Actuate Cash from 2010 to 2026
| ACTU Stock | 4.41 0.09 2.08% |
Cash | First Reported 2010-12-31 | Previous Quarter 7.8 M | Current Value 8.5 M | Quarterly Volatility 6 M |
Check Actuate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actuate Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 191.9 K, Interest Income of 220.7 K or Depreciation And Amortization of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4 K. Actuate financial statements analysis is a perfect complement when working with Actuate Therapeutics Valuation or Volatility modules.
Actuate | Cash | Build AI portfolio with Actuate Stock |
The evolution of Cash for Actuate Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Actuate Therapeutics compares to historical norms and industry peers.
Latest Actuate Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Actuate Therapeutics Common over the last few years. Cash refers to the most liquid asset of Actuate Therapeutics, which is listed under current asset account on Actuate Therapeutics Common balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Actuate Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Actuate Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Actuate Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Actuate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Actuate Cash Regression Statistics
| Arithmetic Mean | 17,280,313 | |
| Geometric Mean | 15,570,496 | |
| Coefficient Of Variation | 34.75 | |
| Mean Deviation | 4,846,701 | |
| Median | 20,449,310 | |
| Standard Deviation | 6,004,543 | |
| Sample Variance | 36.1T | |
| Range | 17.5M | |
| R-Value | (0.71) | |
| Mean Square Error | 19.3T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (838,785) | |
| Total Sum of Squares | 576.9T |
Actuate Cash History
Other Fundumenentals of Actuate Therapeutics
Actuate Therapeutics Cash component correlations
Click cells to compare fundamentals
About Actuate Therapeutics Financial Statements
Actuate Therapeutics shareholders use historical fundamental indicators, such as Cash, to determine how well the company is positioned to perform in the future. Although Actuate Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Actuate Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Actuate Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash | 7.8 M | 8.5 M | |
| Cash And Short Term Investments | 7.8 M | 8.5 M | |
| Change In Cash | 6.5 M | 6.9 M | |
| Free Cash Flow | -19.7 M | -20.6 M | |
| Begin Period Cash Flow | 2.7 M | 2.5 M | |
| Other Cashflows From Financing Activities | -1.7 M | -1.7 M | |
| Other Non Cash Items | 2.7 M | 2.8 M | |
| Total Cash From Operating Activities | -19.7 M | -20.6 M | |
| Total Cash From Financing Activities | 31.7 M | 18.7 M | |
| End Period Cash Flow | 7.8 M | 8.5 M | |
| Free Cash Flow Yield | (0.16) | (0.17) | |
| Operating Cash Flow Per Share | (1.01) | (1.06) | |
| Free Cash Flow Per Share | (1.01) | (1.06) | |
| Cash Per Share | 0.51 | 0.74 | |
| EV To Operating Cash Flow | (7.72) | (8.11) | |
| EV To Free Cash Flow | (7.72) | (8.11) | |
| Price To Operating Cash Flows Ratio | (6.40) | (6.72) | |
| Price To Free Cash Flows Ratio | (6.40) | (6.72) | |
| Cash Ratio | 1.13 | 2.24 | |
| Cash Flow Coverage Ratios | (39.54) | (41.52) | |
| Price Cash Flow Ratio | (6.40) | (6.72) | |
| Cash Flow To Debt Ratio | (39.54) | (41.52) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.